Siân E. Faustini, Lauren M. Quinn, Madeeha Hoque, Siobhan Young, Christopher Bentley, Hin-Fai Kwok, Timothy Plant, Ian Litchfield, Felicity Boardman, Sheila M. Greenfield, Parth Narendran, Alex G. Richter
{"title":"Establishing the performance and acceptability of dried blood spot sampling to screen for islet-specific autoantibodies","authors":"Siân E. Faustini, Lauren M. Quinn, Madeeha Hoque, Siobhan Young, Christopher Bentley, Hin-Fai Kwok, Timothy Plant, Ian Litchfield, Felicity Boardman, Sheila M. Greenfield, Parth Narendran, Alex G. Richter","doi":"10.1111/dme.70071","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Islet-specific autoantibodies predate and predict the onset of type 1 diabetes and can be used to screen for presymptomatic disease. Dried blood spots (DBS) offer a convenient and reliable method for community-based capillary sampling requiring low blood volumes compared to venous collection. We aimed to verify the use of DBS for detecting autoantibodies by the ElisaRSR (3-screen) multiplex assay compared to venous sampling and also explore the acceptability of DBS sampling.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Paired serum and DBS samples were collected from healthy controls (HC) and individuals with type 1 diabetes on insulin. Validation and verification of a 3-screen Islet cell autoantibody (IA-2A, GADA and ZnT8A) ELISA assay was undertaken for both matrices and compared. Perceived acceptability of DBS testing was explored via semi-structured interviews with parents and professional stakeholders.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Temporally paired serum and DBS samples were collected for 101 individuals with type 1 diabetes (aged 7–73 years) and 22 HC (aged 18–60 years). Performance characteristics were similar for serum and DBS; sensitivity for serum was 86% compared to 89% for DBS and a specificity of 97% for serum compared to 100% for DBS. Parents (<i>n</i> = 38) and stakeholders (<i>n</i> = 25) thought DBS testing offered a minimally invasive, convenient screening test. Parents emphasised choice of screening location, including home and community settings.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>DBS sampling can be used as an alternative to serum for use with the 3-screen assay for general population type 1 diabetes autoantibody screening. DBS sampling appears acceptable to parents and stakeholders.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"42 8","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.70071","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.70071","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Islet-specific autoantibodies predate and predict the onset of type 1 diabetes and can be used to screen for presymptomatic disease. Dried blood spots (DBS) offer a convenient and reliable method for community-based capillary sampling requiring low blood volumes compared to venous collection. We aimed to verify the use of DBS for detecting autoantibodies by the ElisaRSR (3-screen) multiplex assay compared to venous sampling and also explore the acceptability of DBS sampling.
Methods
Paired serum and DBS samples were collected from healthy controls (HC) and individuals with type 1 diabetes on insulin. Validation and verification of a 3-screen Islet cell autoantibody (IA-2A, GADA and ZnT8A) ELISA assay was undertaken for both matrices and compared. Perceived acceptability of DBS testing was explored via semi-structured interviews with parents and professional stakeholders.
Results
Temporally paired serum and DBS samples were collected for 101 individuals with type 1 diabetes (aged 7–73 years) and 22 HC (aged 18–60 years). Performance characteristics were similar for serum and DBS; sensitivity for serum was 86% compared to 89% for DBS and a specificity of 97% for serum compared to 100% for DBS. Parents (n = 38) and stakeholders (n = 25) thought DBS testing offered a minimally invasive, convenient screening test. Parents emphasised choice of screening location, including home and community settings.
Conclusions
DBS sampling can be used as an alternative to serum for use with the 3-screen assay for general population type 1 diabetes autoantibody screening. DBS sampling appears acceptable to parents and stakeholders.
期刊介绍：
Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions.
The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed.
We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services.
Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
